ClinicalTrials.Veeva

Menu

Duodenal Jejunal Bypass for Type 2 Diabetes (DJBD)

F

Ferzli, George S., M.D. F.A.C.S.

Status and phase

Unknown
Phase 1

Conditions

Diabetes Mellitus

Treatments

Procedure: duodenal jejunal bypass

Study type

Interventional

Identifiers

NCT00487526
AS07006

Details and patient eligibility

About

Study the effect of Duodenal jejunal bypass on human adults with type 2 diabetes.

Full description

Adults non obese ( BMI less than 34 ) will undergo duodenal jejunal bypass. The Outcome measures: Blood Sugar, Insulin,HbA1c, CCK,Gastrin, GIP1and 2, Ghrelin, Cholesterol, Triglycerides,FFA, C-Peptide.

Enrollment

50 estimated patients

Sex

All

Ages

20 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults age 20-65
  • Clinical diagnosis of type 2 diabetes
  • Non obese with BMI less than 34.
  • Oral agents or insulin to control T2DM.
  • Inadequate control of diabetes as defined as HbA1c>/7.5
  • Understanding of the mechanisms of action of the treatment

Exclusion criteria

  • Children with type 1 diabetes
  • Obese with BMI over 34
  • Coagulopathy
  • Liver cirrhosis
  • Unable to comply with study requirements, follow-up or give valid consent
  • Currently pregnant
  • Previous upper abdominal surgery
  • Inabilty to tolerate general anesthesia

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Central trial contact

George S Ferzli, MD, F.A.C.S

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems